Our CU Lymphoma Program faculty Dr. Ajay Major, MD, MBA contributed to a multicenter study of venetoclax in relapsed/refractory Waldenstrom macroglobulinemia, now published Blood Cancer Journal. #lymsm pmc.ncbi.nlm.nih.gov/articles/PMC12…

We love to see this collaboration! imPROve is one of many Work in Progress (WIP) groups hosted by ACCORDS to facilitate meeting and collaboration around specific topic areas in health services research. Learn more: medschool.cuanschutz.edu/accords/resear…

We are seeking patients with relapsed or refractory FL or DLBCL for a compensated study about experiences with bispecific antibody therapies. To my #lymsm & #onctwitter colleagues: please share the attached flyer with your networks. Thank you! #tcellrx

Checking in at #XGM2025! Many thanks for the invitation to speak on our implementation of the eSyM electronic symptom monitoring platform CU Cancer Center as part of the PCORI-funded OncoPRO initiative. #onctwitter

Come join us this morning at #XGM2025 to learn about integration of eSyM remote symptom monitoring in patients with cancer, including our experience CU Cancer Center CU Lymphoma Program. #onctwitter

Elated to be joining the ASH Clinical Research Training Institute (CRTI) in 2025! Eager to work on our research program utilizing PROs to improve treatment decision-making in indolent lymphomas. Deeply grateful to my mentors Drs. Jamie L. Studts, PhD & manalikamdar. #lymsm

Happy #NationalHospitalWeek 🥳 Let's take a moment to celebrate the incredible individuals who make our hospitals a place of healing, hope, and compassion. This week is for you! 👏

Excited to share our latest paper calling for a modernized approach to AE measurement, analysis, visualization, & reporting led by Ajay Major, MD, MBA! 📊🧬#hematology #ClinicalTrials #lymsm #dataviz authors.elsevier.com/c/1lAZ98MsWYNW…

Congratulations to our CU Lymphoma Program faculty Dr. Ajay Major, MD, MBA on publication of the first installation of the The Lancet Haematology Commission on Adverse Event Reporting! thelancet.com/series-do/adve… cc CU Cancer Center CU Department of Medicine CU Anschutz Medical Campus CU School of Medicine

Modern therapeutics call for a modernized approach to measuring, analyzing and reporting adverse events! Read our The Lancet Haematology paper for the Commission on Adverse Event Reporting, with Amylou Dueck, PhD & Gita Thanarajasingam thelancet.com/journals/lanha… #clinicaltrial #dataviz

You made my day James !!! Thank you !!!

Navigating CART for Lymphoma in 2025 - great session at #EHA2025 with manalikamdar Kai Rejeski and the OG Prof Zinzani #CART #lymsm

Great to join Paul Bröckelmann presenting data from our recent The Lancet Haematology commission on adverse events, starting with the paper by Ajay Major, MD, MBA Amylou Dueck, PhD on advancing AE measurement #EHA2025 Gita Thanarajasingam

Next Paul Bröckelmann highlighting these very nice tables from Ajay Major, MD, MBA Amylou Dueck, PhD on new dashboards for better capturing AEs #EHA2025 #EHA25 The Lancet Haematology YoungEHA European Hematology Association

For those missing the #EHA2025 fun, a #podcast discussing the The Lancet Haematology Commission topic of better adverse event assessment was just posted! buzzsprout.com/1564352/episod… Paul Bröckelmann Ajay Major, MD, MBA, Gita Thanarajasingam (also features Vishal Bhatnagar & Lan-Lan Smith not on X)

If you want to hear more from the authors of the first set of commission manuscripts, our The Lancet Haematology podcast is now online! buzzsprout.com/1564352/episod… ft. Gita Thanarajasingam Amylou Dueck, PhD Paul Bröckelmann #EHA2025

Congratulations to all the CUBIC investigators, led by Dr. drsairahahmed! We are proud to contribute to this growing bispecific registry at CU Lymphoma Program. cc manalikamdar #18ICML #lymsm

Congratulations to our CU Lymphoma Program lead Dr. manalikamdar on her first-author publication in Journal of Clinical Oncology about the 3-year follow-up of TRANSFORM! ascopubs.org/doi/10.1200/JC… #lymsm #tcellrx

A huge congratulations to CU Internal Medicine resident physician Dr. Vinny Pizzuti on his ASH HONORS Award with mentor and CU Lymphoma Program lead Dr. manalikamdar! #lymsm cc CU School of Medicine CU Anschutz Medical Campus CU Internal Medicine

Our CU Lymphoma Program faculty Dr. Ajay Major, MD, MBA contributed to a large multicenter study of bispecific antibody therapy outcomes, published Blood Journals Portfolio. #lymsm #tcellrx cc CU Anschutz Medical Campus CU Cancer Center CU Anschutz Division of Hematology